Search
Atossa Therapeutics Inc
ATOSAdd to Watchlist
2.650USD
-0.130-4.68%
Close 10-15 16:00（ET）
26.42MMarket Cap
LossP/E TTM
Atossa Therapeutics Inc (ATOS) Stock Price Target & Forecast
Analyst Rating
Based on 2 analysts giving stock ratings to Atossa Therapeutics Inc in the past month.
Buy
0 Strong Buy
2 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
19.000USD+642.19%
ATOS Analyst Recommendation Trends
In the current month, ATOS has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ATOS average Analyst price target in the last month is 19.000.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
0
0
0
0
0
0
0
0
2
2
2
2
3
3
4
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
3
3
4
4
ATOS Analyst Rating for Peer Comparison
Updated: Oct 15, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
Revolution Medicines Inc
RVMD
9
14
1
0
0
24
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
7
0
0
23
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Financial Forecasting
Based on analysts' estimates, ATOS EPS is projected to reach -0.890 in FY2026Q3, following reported EPS of -0.953 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.14
-6.12
-1.02
-0.89
-0.86
Actual
-1.27
-1.11
-0.95
--
--
Surprise
-11.66%
+81.84%
+7.01%
--
--
FAQs
What is Atossa Therapeutics Inc's price target?
Analysts forecast that Atossa Therapeutics Inc's price target is USD 19.00, with the highest forecast at USD 25.00 and the lowest forecast at USD 10.00.
How have Atossa Therapeutics IncATOS's recent earnings per share performed?
The market expectation was USD -0.95, while Atossa Therapeutics IncATOS's earnings per share (EPS) for the previous quarter was USD -1.11. EPS for the next quarter is expected at USD -0.89.
What is the analyst rating for Atossa Therapeutics Inc?
Based on the ratings of Atossa Therapeutics Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.